Optimal Dose of Misoprostol combined with Oxytocin for Preventing Postpartum Hemorrhage in Cesarean Section

Intrauterine Misoprostol Combined with Oxytocin for Reducing Blood Loss during Cesarean Delivery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211102001

Enrollment

300

Registered

2021-11-02

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum hemorrhage Misoprostal Oxytocin Blood loss cesarean section

Interventions

Intrauterine misoprostol,intrauterine misoprostol,Intrauterine misoprostol

Active Comparator Drug,Active Comparator Drug,Active Comparator Drug

800 microgram, 600 microgram, 400 microgram

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: inpatient department of OB-GYN unit who indicated for cesarean section.

Exclusion criteria

Exclusion criteria: Our patients no contraindication for administrated misoprostol The patient who reported co-morbid diseases of bleeding tendency

Design outcomes

Primary

Measure	Time frame
Blood loss immediate postoperative estimate blood loss	—

Secondary

Measure	Time frame
Side effect of misoprostol within 24 hours post operative Clinical sign and symptom	—

Countries

Thailand

Contacts

Public ContactSurasak Saokeaw

Phayao Hospital

surasak.sa@up.ac.th0924056691

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026